233 related articles for article (PubMed ID: 17878803)
21. The response of spinal cord ependymomas to bevacizumab in patients with neurofibromatosis Type 2.
J Neurosurg Spine; 2017 Apr; 26(4):474-482. PubMed ID: 27982762
[TBL] [Abstract][Full Text] [Related]
22. The neurofibromatoses. Part 2: NF2 and schwannomatosis.
Lu-Emerson C; Plotkin SR
Rev Neurol Dis; 2009; 6(3):E81-6. PubMed ID: 19898272
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of NF2 gene deletion in sporadic schwannomas, meningiomas, and ependymomas by chromogenic in situ hybridization.
Begnami MD; Palau M; Rushing EJ; Santi M; Quezado M
Hum Pathol; 2007 Sep; 38(9):1345-50. PubMed ID: 17509660
[TBL] [Abstract][Full Text] [Related]
24. A comparative study of embedded nerve tissue in six NF2-associated schwannomas and 17 nonassociated NF2 schwannomas.
Hamada Y; Iwaki T; Fukui M; Tateishi J
Surg Neurol; 1997 Oct; 48(4):395-400. PubMed ID: 9315139
[TBL] [Abstract][Full Text] [Related]
25. Clinical manifestations of mutations in the neurofibromatosis type 2 gene in vestibular schwannomas (acoustic neuromas).
Welling DB
Laryngoscope; 1998 Feb; 108(2):178-89. PubMed ID: 9473065
[TBL] [Abstract][Full Text] [Related]
26. Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2.
Sun S; Liu A
J Neurosurg; 2014 Dec; 121 Suppl():143-9. PubMed ID: 25434947
[TBL] [Abstract][Full Text] [Related]
27. Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2-associated gliomas to be spinal ependymomas.
Hagel C; Stemmer-Rachamimov AO; Bornemann A; Schuhmann M; Nagel C; Huson S; Evans DG; Plotkin S; Matthies C; Kluwe L; Mautner VF
Neuropathology; 2012 Dec; 32(6):611-6. PubMed ID: 22394059
[TBL] [Abstract][Full Text] [Related]
28. A group of schwannomas with interstitial deletions on 22q located outside the NF2 locus shows no detectable mutations in the NF2 gene.
Bruder CE; Ichimura K; Tingby O; Hirakawa K; Komatsuzaki A; Tamura A; Yuasa Y; Collins VP; Dumanski JP
Hum Genet; 1999 May; 104(5):418-24. PubMed ID: 10394935
[TBL] [Abstract][Full Text] [Related]
29. Combined molecular genetic studies of chromosome 22q and the neurofibromatosis type 2 gene in central nervous system tumors.
Ng HK; Lau KM; Tse JY; Lo KW; Wong JH; Poon WS; Huang DP
Neurosurgery; 1995 Oct; 37(4):764-73. PubMed ID: 8559307
[TBL] [Abstract][Full Text] [Related]
30. Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2.
Farschtschi S; Merker VL; Wolf D; Schuhmann M; Blakeley J; Plotkin SR; Hagel C; Mautner VF
Acta Neurol Scand; 2016 Jun; 133(6):475-80. PubMed ID: 26369495
[TBL] [Abstract][Full Text] [Related]
31. Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism.
Wong HK; Shimizu A; Kirkpatrick ND; Garkavtsev I; Chan AW; di Tomaso E; Klagsbrun M; Jain RK
Neoplasia; 2012 Feb; 14(2):84-94. PubMed ID: 22431917
[TBL] [Abstract][Full Text] [Related]
32. [Neurofibromatosis type 2 (central neurofibromatosis or bilateral acoustic neuromas, vestibular schwannomas): from phenotype to gene].
Sabol Z; Kipke-Sabol L; Miklić P; Hajnsek-Propadalo S; Sabol F
Lijec Vjesn; 2006; 128(9-10):309-16. PubMed ID: 17128670
[TBL] [Abstract][Full Text] [Related]
33. Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients.
Ruggieri M; Iannetti P; Polizzi A; La Mantia I; Spalice A; Giliberto O; Platania N; Gabriele AL; Albanese V; Pavone L
Neuropediatrics; 2005 Feb; 36(1):21-34. PubMed ID: 15776319
[TBL] [Abstract][Full Text] [Related]
34. Advances in the treatment of neurofibromatosis-associated tumours.
Lin AL; Gutmann DH
Nat Rev Clin Oncol; 2013 Nov; 10(11):616-24. PubMed ID: 23939548
[TBL] [Abstract][Full Text] [Related]
35. Multiple cutaneous plexiform schwannomas as initial presentation of neurofibromatosis 2 in a 9-year-old.
Nguyen TV; Matthews MR; Barrera FF; Browning JC
Pediatr Dermatol; 2012; 29(4):536-8. PubMed ID: 21906157
[TBL] [Abstract][Full Text] [Related]
36. Clinical course of vestibular schwannoma in pediatric neurofibromatosis Type 2.
Choi JW; Lee JY; Phi JH; Wang KC; Chung HT; Paek SH; Kim DG; Park SH; Kim SK
J Neurosurg Pediatr; 2014 Jun; 13(6):650-7. PubMed ID: 24724714
[TBL] [Abstract][Full Text] [Related]
37. Probability of bilateral disease in people presenting with a unilateral vestibular schwannoma.
Evans DG; Lye R; Neary W; Black G; Strachan T; Wallace A; Ramsden RT
J Neurol Neurosurg Psychiatry; 1999 Jun; 66(6):764-7. PubMed ID: 10329751
[TBL] [Abstract][Full Text] [Related]
38. Immunoblotting analysis of schwannomin/merlin in human schwannomas.
Harwalkar JA; Lee JH; Hughes G; Kinney SE; Golubić M
Am J Otol; 1998 Sep; 19(5):654-9. PubMed ID: 9752976
[TBL] [Abstract][Full Text] [Related]
39. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas.
Antinheimo J; Sankila R; Carpén O; Pukkala E; Sainio M; Jääskeläinen J
Neurology; 2000 Jan; 54(1):71-6. PubMed ID: 10636128
[TBL] [Abstract][Full Text] [Related]
40. CNS Young Investigator Award Lecture: molecular analysis of the neurofibromatosis 2 tumor suppressor.
MacCollin M
Brain Dev; 1995; 17(4):231-8. PubMed ID: 7503383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]